 phase IA trial sequenti administr recombin dna-produc interferon combin recombin interferon gamma recombin interferon alfa patient metastat renal cell carcinoma studi effect recombin interferon gamma rifn gamma recombin interferon alfa rifn alpha patient metastat renal cell carcinoma rcc rifn alpha day dosag cohort patient cohort patient dose rifn alpha subset patient rifn gamma gamma day third week hour administr rifn alpha dose-limit toxic dlt constitut symptom leukopenia nephrot syndrom acut renal failur hypotens death congest heart failur dlt rifn alpha gamma dose level maximum-toler dose mtd rifn alpha rifn gamma patient minimum day therapi due toxic rapid progress diseas clinic respons assess patient patient complet remiss complet remiss month addit patient partial respons month patient partial remiss slow regress pulmonari liver lesion therapi rifn clinic respons durabl patient complet remiss patient partial remiss result studi toxic combin rifn therapi agent